“pompe-disease” Archives

Entry Author Date Location
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More 10/06/17 National
Amicus Therapeutics’ Pompe Drug Data Show Improved Muscle Movement 10/04/17 New York
Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval 07/20/16 San Francisco
Amicus Wheels, Deals, Restructures Following Fabry Drug Setback 11/20/13 New York
Amicus, Biogen Team Up on Parkinson’s Drug Deal 09/10/13 Boston
Audentes, Loaded With $30M, Pursues Gene Therapy for Rare Diseases 07/26/13 San Francisco
Henri Termeer on Startups, Drug Prices, Getting Older (Part 2) 05/14/13 National
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments 01/11/12 New York
BioMarin Buys ZyStor For $115M 08/18/10 San Francisco
FDA Approves Genzyme Pompe Drug, Vertex Hepatitis C Drug Trial Succeeds, Thermo Fisher Acquires Fermentas, & More Boston-Area Life Sciences News 05/28/10 Boston
Genzyme Gets FDA Nod for Pompe Drug 05/25/10 Boston
FDA to Rule on Genzyme Drug in Six Months 01/21/10 Boston
FDA Shoots Down Genzyme’s Latest Bid for Pompe Drug Approval 11/16/09 Boston
Genzyme Fails to Win FDA Approval for Large-Scale Production of Pompe Drug 03/02/09 Boston
Genzyme Nabs Two Key Regulatory Approvals, Expected to Trigger Revenue Growth 02/26/09 Boston
FDA Plans To Clear Genzyme’s Myozyme Made at Large Scale 11/17/08 Boston
FDA Panel Favors Genzyme’s Myozyme 10/22/08 Boston
Genzyme Expects FDA Review of Myozyme Factory by Thanksgiving Weekend 09/23/08 Boston
Page 1 of 1